Buchumschlag

Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Akihito Shiomi, Teruki Miyake, Shinya Furukawa, Bunzo Matsuura, Osamu Yoshida, Takao Watanabe, Ayumi Kanamoto, Masumi Miyazaki, Hironobu Nakaguchi, Yoshio Tokumoto, Masashi Hirooka, Masanori Abe, Yoichi Hiasa
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Hepatology Research
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Effect of remnant cholesterol on the onset of diabetes mellitus
von: Teruki Miyake, et al.
Veröffentlicht: (2025)

Fibrosis‐4 Index as a Robust Long‐Term Predictor of Cancers in Metabolic Dysfunction–Associated Steatotic Liver Disease
von: Ayumi Kanamoto, et al.
Veröffentlicht: (2026)

Severe hepatic steatosis promotes increased liver stiffness in the early stages of metabolic dysfunction–associated steatotic liver disease
von: Takashi Kumada, et al.
Veröffentlicht: (2024)

Association of liver fibrosis progression with non–liver‐related mortality in metabolic dysfunction‐associated steatotic liver disease
von: Toshifumi Tada, et al.
Veröffentlicht: (2025)

Serum adropin is unaltered in adolescents with histology‐confirmed steatotic liver disease
von: Jordan A. Bays, et al.
Veröffentlicht: (2024)

Therapeutic management of metabolic dysfunction associated steatotic liver disease
von: Jing Zeng, et al.
Veröffentlicht: (2024)

Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease
von: Takao Miwa, et al.
Veröffentlicht: (2024)

Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Molecular pathogenesis of metabolic dysfunction‐associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis
von: Takashi Saito, et al.
Veröffentlicht: (2024)

Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
von: Rasha Abi Radi Abou Jaoudeh, et al.
Veröffentlicht: (2024)

Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study
von: Hiroki Ono, et al.
Veröffentlicht: (2024)

The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease
von: Hye Won Lee, et al.
Veröffentlicht: (2024)

Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease?
von: Guillaume Henin, et al.
Veröffentlicht: (2024)

Vitamin E improves serum markers and histology in adults with metabolic dysfunction‐associated steatotic liver disease: Systematic review and meta‐analysis
von: Nicholas Ming‐Zher Chee, et al.
Veröffentlicht: (2024)

Treatment of liver cirrhosis in the era of steatotic liver disease
von: Masahito Shimizu
Veröffentlicht: (2024)

Low thyroid function is associated with metabolic dysfunction‐associated steatotic liver disease
von: Shuo Wang, et al.
Veröffentlicht: (2024)

The role of mean platelet volume in metabolic dysfunction associated steatotic liver disease
von: Papagiouvanni Ioanna, et al.
Veröffentlicht: (2025)

Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease?
von: Adele Tulone, et al.
Veröffentlicht: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa
von: Zobair M. Younossi, et al.
Veröffentlicht: (2024)

Pediatricians' practices and knowledge of metabolic dysfunction‐associated steatotic liver disease: An international survey
von: Judith W. Lubrecht, et al.
Veröffentlicht: (2024)

Metabolic dysfunction associated steatotic liver disease—Clinicians should not underestimate the role of steatosis
von: Johannes Wiegand, et al.
Veröffentlicht: (2024)

Vibration‐controlled transient elastography in pediatric metabolic dysfunction‐associated steatotic liver disease
von: Lauren B. Nichols, et al.
Veröffentlicht: (2025)

Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study
von: Yu Peng, et al.
Veröffentlicht: (2025)

Prognostic performance of a two‐step method using the Fibro‐Scope system for metabolic dysfunction‐associated steatotic liver disease
von: Yuya Seko, et al.
Veröffentlicht: (2024)

Thy‐1 restricts steatosis and liver fibrosis in steatotic liver disease
von: Valentin Blank, et al.
Veröffentlicht: (2024)

Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease
von: Yi‐Ting Chen, et al.
Veröffentlicht: (2024)

Performance of continuous controlled attenuation parameter and liver stiffness measurement by the novel SmartExam in metabolic dysfunction‐associated steatotic liver disease
von: Sherlot J. Song, et al.
Veröffentlicht: (2024)

Metabolic dysfunction‐associated steatotic liver disease: A superior predictor for incident type 2 diabetes over traditional criteria – NAGALA study
von: Kimiko Sakai, et al.
Veröffentlicht: (2024)

Waitlist and transplant outcomes in patients with metabolic dysfunction‐associated steatotic liver disease and autoimmune hepatitis
von: Esli Medina‐Morales, et al.
Veröffentlicht: (2024)

Characterization of brain morphology associated with metabolic dysfunction‐associated steatotic liver disease in the UK Biobank
von: Wenxiao Fan, et al.
Veröffentlicht: (2025)

Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction‐associated steatotic liver disease
von: Mohit Kehar, et al.
Veröffentlicht: (2024)

Chitosan and chito-oligosaccharides as multifunctional therapeutics for metabolic dysfunction-associated steatotic liver disease (MASLD).
von: Zhou, Gaoli, et al.
Veröffentlicht: (2026)

Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction‐associated steatotic liver disease
von: Carmen Arto, et al.
Veröffentlicht: (2024)

The immunological interface: dendritic cells as key regulators in metabolic dysfunction‐associated steatotic liver disease
von: Camilla Klaimi, et al.
Veröffentlicht: (2024)

Association between metabolic dysfunction‐associated steatotic liver disease and myosteatosis measured by computed tomography
von: Myung Jin Kim, et al.
Veröffentlicht: (2024)

FISPGHAN statement on the global public health impact of metabolic dysfunction‐associated steatotic liver disease
von: Tania Mitsinikos, et al.
Veröffentlicht: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
von: Nabil Noureddin, et al.
Veröffentlicht: (2024)

Pieris japonica (Ericaceae) Dominance and Increased Organic Horizon Inhibit Plant Establishment in Forests Altered by Deer Grazing
von: Yuji Tokumoto, et al.
Veröffentlicht: (2026)

Development of Automated Software Design Document Review Methods Using Large Language Models
von: Fukuda, Takasaburo, et al.
Veröffentlicht: (2025)